Starpharma Holdings Limited (SPL.AX)
AUD 0.1
(3.19%)
AUD 0.1
(3.19%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 8.28 Million AUD | 182.03% |
| 2023 | 2.93 Million AUD | -37.23% |
| 2022 | 4.68 Million AUD | 160.4% |
| 2021 | 1.79 Million AUD | -70.2% |
| 2020 | 6.03 Million AUD | 121.8% |
| 2019 | 2.72 Million AUD | -45.13% |
| 2018 | 4.95 Million AUD | 35.92% |
| 2017 | 3.64 Million AUD | -20.27% |
| 2016 | 4.57 Million AUD | 169.53% |
| 2015 | 1.69 Million AUD | 35.43% |
| 2014 | 1.25 Million AUD | 6165.0% |
| 2013 | 20 Thousand AUD | -97.84% |
| 2012 | 925 Thousand AUD | -19.14% |
| 2011 | 1.14 Million AUD | -18.52% |
| 2010 | 1.4 Million AUD | -30.46% |
| 2009 | 2.01 Million AUD | 42.99% |
| 2008 | 1.41 Million AUD | 63.45% |
| 2007 | 863.85 Thousand AUD | 172670.8% |
| 2006 | 500.00 AUD | -99.98% |
| 2005 | 2.04 Million AUD | 47.37% |
| 2004 | 1.39 Million AUD | -6.35% |
| 2003 | 1.48 Million AUD | 285.99% |
| 2002 | 384.7 Thousand AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 7.19 Million AUD | 0.0% |
| 2024 Q4 | 1.73 Million AUD | 0.0% |
| 2024 FY | 8.28 Million AUD | 182.03% |
| 2023 Q2 | 1.08 Million AUD | 0.0% |
| 2023 FY | 2.93 Million AUD | -37.23% |
| 2023 Q4 | 1.85 Million AUD | 0.0% |
| 2022 FY | 4.68 Million AUD | 160.4% |
| 2022 Q4 | 2.86 Million AUD | 0.0% |
| 2022 Q2 | 1.81 Million AUD | 0.0% |
| 2021 Q2 | 486 Thousand AUD | 0.0% |
| 2021 Q4 | 1.31 Million AUD | 0.0% |
| 2021 FY | 1.79 Million AUD | -70.2% |
| 2020 Q4 | 680 Thousand AUD | 0.0% |
| 2020 Q2 | 5.35 Million AUD | 0.0% |
| 2020 FY | 6.03 Million AUD | 121.8% |
| 2019 FY | 2.72 Million AUD | -45.13% |
| 2019 Q2 | 661 Thousand AUD | 0.0% |
| 2019 Q4 | 1.56 Million AUD | 0.0% |
| 2018 Q4 | 3.71 Million AUD | 0.0% |
| 2018 FY | 4.95 Million AUD | 35.92% |
| 2018 Q2 | 1.24 Million AUD | 0.0% |
| 2017 Q2 | 549 Thousand AUD | 0.0% |
| 2017 FY | 3.64 Million AUD | -20.27% |
| 2016 FY | 4.57 Million AUD | 169.53% |
| 2016 Q2 | 3.74 Million AUD | 0.0% |
| 2015 Q4 | 964 Thousand AUD | 0.0% |
| 2015 Q2 | 733 Thousand AUD | 0.0% |
| 2015 FY | 1.69 Million AUD | 35.43% |
| 2014 FY | 1.25 Million AUD | 6165.0% |
| 2014 Q4 | 532 Thousand AUD | 0.0% |
| 2014 Q2 | 721 Thousand AUD | 0.0% |
| 2013 Q2 | 1.29 Million AUD | 11672.73% |
| 2013 Q1 | 11 Thousand AUD | 0.0% |
| 2013 Q3 | 5000.00 AUD | -99.61% |
| 2013 Q4 | 1.13 Million AUD | 22680.0% |
| 2013 FY | 20 Thousand AUD | -97.84% |
| 2012 Q1 | 286 Thousand AUD | 0.0% |
| 2012 FY | 925 Thousand AUD | -19.14% |
| 2012 Q4 | 11 Thousand AUD | 0.0% |
| 2012 Q3 | 11 Thousand AUD | 0.0% |
| 2012 Q2 | 11 Thousand AUD | -96.15% |
| 2011 FY | 1.14 Million AUD | -18.52% |
| 2011 Q3 | 286 Thousand AUD | 0.0% |
| 2011 Q1 | 351 Thousand AUD | 0.0% |
| 2011 Q4 | 286 Thousand AUD | 0.0% |
| 2011 Q2 | 286 Thousand AUD | -18.52% |
| 2010 Q3 | 351 Thousand AUD | 0.0% |
| 2010 FY | 1.4 Million AUD | -30.46% |
| 2010 Q2 | 351 Thousand AUD | -30.46% |
| 2010 Q1 | 504.75 Thousand AUD | 0.0% |
| 2010 Q4 | 351 Thousand AUD | 0.0% |
| 2009 Q2 | 504.75 Thousand AUD | 42.99% |
| 2009 Q3 | 504.75 Thousand AUD | 0.0% |
| 2009 Q4 | 504.75 Thousand AUD | 0.0% |
| 2009 Q1 | 353 Thousand AUD | 0.0% |
| 2009 FY | 2.01 Million AUD | 42.99% |
| 2008 Q2 | 353 Thousand AUD | 63.45% |
| 2008 Q3 | 353 Thousand AUD | 0.0% |
| 2008 FY | 1.41 Million AUD | 63.45% |
| 2008 Q4 | 353 Thousand AUD | 0.0% |
| 2008 Q1 | 215.96 Thousand AUD | 0.0% |
| 2007 FY | 863.85 Thousand AUD | 172670.8% |
| 2007 Q4 | 215.96 Thousand AUD | 0.0% |
| 2007 Q1 | 125.00 AUD | 0.0% |
| 2007 Q3 | 215.96 Thousand AUD | 0.0% |
| 2007 Q2 | 215.96 Thousand AUD | 172670.4% |
| 2006 Q1 | 3480.50 AUD | 0.0% |
| 2006 Q4 | 125.00 AUD | 0.0% |
| 2006 Q3 | 125.00 AUD | 0.0% |
| 2006 FY | 500.00 AUD | -99.98% |
| 2006 Q2 | 125.00 AUD | -96.41% |
| 2005 FY | 2.04 Million AUD | 47.37% |
| 2005 Q3 | 3480.50 AUD | 0.0% |
| 2005 Q4 | 3480.50 AUD | 0.0% |
| 2005 Q2 | 3480.50 AUD | -11.49% |
| 2005 Q1 | 3932.50 AUD | 0.0% |
| 2004 Q4 | 3932.50 AUD | 0.0% |
| 2004 Q1 | 227.83 Thousand AUD | 0.0% |
| 2004 Q2 | 3932.50 AUD | -98.27% |
| 2004 Q3 | 3932.50 AUD | 0.0% |
| 2004 FY | 1.39 Million AUD | -6.35% |
| 2003 Q2 | 227.83 Thousand AUD | 136.89% |
| 2003 Q4 | 227.83 Thousand AUD | 0.0% |
| 2003 Q3 | 227.83 Thousand AUD | 0.0% |
| 2003 Q1 | 96.17 Thousand AUD | 0.0% |
| 2003 FY | 1.48 Million AUD | 285.99% |
| 2002 Q4 | 96.17 Thousand AUD | 0.0% |
| 2002 Q3 | 96.17 Thousand AUD | 0.0% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 Q2 | 96.17 Thousand AUD | 0.0% |
| 2002 FY | 384.7 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 Q2 | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2001 Q3 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1999 Q1 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1998 Q4 | - AUD | 0.0% |
| 1998 Q2 | - AUD | 0.0% |
| 1998 Q3 | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acrux Limited | 5.09 Million AUD | -62.817% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -11.147% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 27.963% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 90.6% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 96.426% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -2670.128% |
| AdAlta Limited | 1.73 Million AUD | -376.983% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -106.231% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1277.322% |
| BTC Health Limited | 16.36 Thousand AUD | -50566.259% |
| CSL Limited | 22.41 Billion AUD | 99.963% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 87.525% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | -136.442% |
| Memphasys Limited | 60 Thousand AUD | -13715.0% |
| Noxopharm Limited | 2.4 Million AUD | -245.335% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -123.281% |
| Race Oncology Limited | 4 Million AUD | -107.045% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -5344.693% |
| Biotron Limited | - AUD | -Infinity% |
| Biome Australia Limited | 13 Million AUD | 36.282% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -45145.633% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -8629.674% |
| Patrys Limited | 1.39 Million AUD | -494.55% |
| Orthocell Limited | 5.31 Million AUD | -55.944% |
| Imugene Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 22.05 Million AUD | 62.424% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -829.111% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -257.957% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -48658.824% |
| Nanollose Limited | 12.5 Thousand AUD | -66206.695% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -583.766% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -86.155% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -562.286% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 98.331% |
| Dimerix Limited | 583.47 Thousand AUD | -1320.619% |
| PharmAust Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -1700.403% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -12497.264% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -1650.392% |
| Actinogen Medical Limited | 9.93 Million AUD | 16.538% |
| Immuron Limited | 4.9 Million AUD | -69.064% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -219.061% |